Viatris (VTRS, Financial) has submitted applications to Japan's Ministry of Health, Labor and Welfare, seeking approval for Effexor SR capsules. This medication, a serotonin-noradrenaline reuptake inhibitor, is designed to treat adults suffering from generalized anxiety disorder (GAD) and could become the first approved treatment for this condition in Japan.
The approval request follows a successful Phase 3 study conducted in Japan. The study was placebo-controlled, randomized, double-blind, and multicenter, focusing on the drug's effectiveness in alleviating symptoms of GAD. Results demonstrated the drug's superiority in reducing anxiety symptoms compared to a placebo after eight weeks of treatment, as measured by the Hamilton Anxiety Rating Scale.
In addition to achieving its primary endpoint, the study met all seven secondary efficacy endpoints outlined in the trial protocol. Moreover, data from a long-term extension study evaluating the effects of venlafaxine on Japanese outpatients with GAD were also included in the application to support its efficacy and safety profile.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Viatris Inc (VTRS, Financial) is $15.37 with a high estimate of $35.00 and a low estimate of $10.00. The average target implies an upside of 103.33% from the current price of $7.56. More detailed estimate data can be found on the Viatris Inc (VTRS) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Viatris Inc's (VTRS, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Viatris Inc (VTRS, Financial) in one year is $9.40, suggesting a upside of 24.34% from the current price of $7.56. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Viatris Inc (VTRS) Summary page.
